These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38833140)

  • 1. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.
    Zhang L; Zhang W; Xu Y; Dong L; Sun Y; Jia Y; Li Z; Chen B; Hou J; Zhang J
    Adv Ther; 2024 Jul; 41(7):2953-2965. PubMed ID: 38833140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.
    Li Z; Radin A; Li M; Hamilton JD; Kajiwara M; Davis JD; Takahashi Y; Hasegawa S; Ming JE; DiCioccio AT; Li Y; Kovalenko P; Lu Q; Ortemann-Renon C; Ardeleanu M; Swanson BN
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):742-755. PubMed ID: 32348036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.
    Nemoto O; Furue M; Nakagawa H; Shiramoto M; Hanada R; Matsuki S; Imayama S; Kato M; Hasebe I; Taira K; Yamamoto M; Mihara R; Kabashima K; Ruzicka T; Hanifin J; Kumagai Y
    Br J Dermatol; 2016 Feb; 174(2):296-304. PubMed ID: 26409172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial.
    Zhao Y; Li JY; Yang B; Ding YF; Wu LM; Zhang LT; Wang JY; Lu QJ; Zhang CL; Zhang FR; Zhu XH; Li YM; Tao XH; Diao QC; Li LF; Lu JY; Man XY; Li FQ; Xia XJ; Song JR; Jia YM; Zhang LB; Chen B; Zhang JZ
    BioDrugs; 2024 Sep; 38(5):681-689. PubMed ID: 39080181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study.
    Danto SI; Tsamandouras N; Reddy P; Gilbert S; Mancuso J; Page K; Peeva E; Vincent MS; Beebe JS
    J Clin Pharmacol; 2024 May; 64(5):529-543. PubMed ID: 37772436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study.
    Yang L; Fang Y; Luo Y; Fu M; Shen K; Luo Z
    Expert Opin Investig Drugs; 2024 Jul; 33(7):741-752. PubMed ID: 38805242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects.
    Parnes JR; Sullivan JT; Chen L; Dias C
    Clin Pharmacol Ther; 2019 Aug; 106(2):441-449. PubMed ID: 30779339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
    Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study.
    Wynne CJ; Cole A; Lemech C; Wang G; Zhang Y; Chen B; Wang M; Li B; Xia M; Sinclair R
    Dermatol Ther (Heidelb); 2023 Oct; 13(10):2357-2373. PubMed ID: 37668898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies.
    Yang Y; Qiu H; Fan Y; Zhang Q; Qin H; Wu J; Zhang X; Liu Y; Zhou R; Zhang Q; Ye Z; Ma J; Xu Y; Feng S; Fei Y; Li N; Cui X; Dong F; Wang Q; Shen K; Shakib S; Williams J; Hu W
    Alzheimers Res Ther; 2024 Oct; 16(1):218. PubMed ID: 39390616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I Dose-Escalation Study of The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Polyethylene Glycol-Erythropoietin (PEG-EPO) in Healthy Subjects.
    Hu C; Sun W; Wu Y; Huang J; Zhang X; Zhang L
    Clin Ther; 2024 Aug; 46(8):636-643. PubMed ID: 39117488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
    Guérard N; Morand O; Dingemanse J
    Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
    Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
    Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis.
    Nnane I; Frederick B; Yao Z; Raible D; Shu C; Badorrek P; van den Boer M; Branigan P; Duffy K; Baribaud F; Fink D; Yang TY; Xu Z
    Br J Clin Pharmacol; 2020 Dec; 86(12):2507-2518. PubMed ID: 32415720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies.
    Clot PF; Kamal M; Sun J; Xu C; Kong F; Gu Y; Yang N; Yin W; Chen B; Ming JE; Yuan Y
    Int Immunopharmacol; 2021 Oct; 99():107985. PubMed ID: 34435584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers.
    Deiteren A; Bontinck L; Conickx G; Vigan M; Dervaux N; Gassiot M; Bas S; Suratt B; Staudinger H; Krupka E
    Clin Transl Sci; 2024 Jun; 17(6):e13864. PubMed ID: 38924698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects.
    Hussaini A; Mukherjee R; Berdieva DM; Glogowski C; Mountfield R; Ho PTC
    Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.